A revolutionary genomic test is offering hope to breast cancer patients by potentially sparing them from grueling chemotherapy. Early trial results suggest that patients with a low test score could be treated with hormone therapy alone and achieve near-identical outcomes to those undergoing chemotherapy.

This breakthrough represents a significant shift in cancer treatment strategy, moving toward more personalized medicine that reduces unnecessary toxicity while maintaining effectiveness. For millions of patients worldwide, this could mean fewer side effects, better quality of life during treatment, and the same survival prospects. Read the full story →

Today's takeaway: Science is increasingly helping us treat disease smarter, not just harder—sparing patients suffering while keeping them well.